Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698333 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
A Phase 2 study of Plaque Psoriasis, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT01698333 is a Phase 2 study of Plaque Psoriasis that has completed, run by Therapeutics. The registered enrollment target is 25 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01698333, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.
Conditions Studied
Interventions
- DRUG 122-0551
Study Locations (3)
California
- Anaheim Clinical Trials - Anaheim
- Therapeutics Clinical Research - San Diego
Texas
- DermResearch, Inc. - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01698333
The ClinicalTrials.gov registry entry for NCT01698333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which 122-0551 is the first listed.
NCT01698333 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT01698333 about?
NCT01698333 is a clinical study titled "Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression". Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.
What is the current status of trial NCT01698333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-04. Estimated completion is 2013-07.
What conditions does trial NCT01698333 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT01698333?
The interventions under investigation include: 122-0551 (DRUG).
Who is sponsoring clinical trial NCT01698333?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01698333 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.